Advances in Microfluidic Blood–Brain Barrier (BBB) Models

Arianna Oddo, Bo Peng, Ziqiu Tong, Yingkai Wei, Wing Yin Tong, Helmut Thissen, Nicolas Hans Voelcker

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Therapeutic options for neurological disorders currently remain limited. The intrinsic complexity of the brain architecture prevents potential therapeutics from reaching their cerebral target, thus limiting their efficacy. Recent advances in microfluidic technology and organ-on-chip systems have enabled the development of a new generation of in vitro platforms that can recapitulate complex in vivo microenvironments and physiological responses. In this context, microfluidic-based in vitro models of the blood–brain barrier (BBB) are of particular interest as they provide an innovative approach for conducting research related to the brain, including modeling of neurodegenerative diseases and high-throughput drug screening. Here, we present the most recent advances in BBB-on-chip devices and examine validation steps that will strengthen their future applications.

Original languageEnglish
Number of pages20
JournalTrends in Biotechnology
DOIs
Publication statusAccepted/In press - 23 May 2019

Keywords

  • blood–brain barrier
  • brain disorders
  • drug screening
  • in vitro models
  • microfluidics
  • organ-on-chip

Cite this

@article{4a210d3fe01443f1beb530c50725413d,
title = "Advances in Microfluidic Blood–Brain Barrier (BBB) Models",
abstract = "Therapeutic options for neurological disorders currently remain limited. The intrinsic complexity of the brain architecture prevents potential therapeutics from reaching their cerebral target, thus limiting their efficacy. Recent advances in microfluidic technology and organ-on-chip systems have enabled the development of a new generation of in vitro platforms that can recapitulate complex in vivo microenvironments and physiological responses. In this context, microfluidic-based in vitro models of the blood–brain barrier (BBB) are of particular interest as they provide an innovative approach for conducting research related to the brain, including modeling of neurodegenerative diseases and high-throughput drug screening. Here, we present the most recent advances in BBB-on-chip devices and examine validation steps that will strengthen their future applications.",
keywords = "blood–brain barrier, brain disorders, drug screening, in vitro models, microfluidics, organ-on-chip",
author = "Arianna Oddo and Bo Peng and Ziqiu Tong and Yingkai Wei and Tong, {Wing Yin} and Helmut Thissen and Voelcker, {Nicolas Hans}",
year = "2019",
month = "5",
day = "23",
doi = "10.1016/j.tibtech.2019.04.006",
language = "English",
journal = "Trends in Biotechnology",
issn = "0167-7799",
publisher = "Elsevier",

}

Advances in Microfluidic Blood–Brain Barrier (BBB) Models. / Oddo, Arianna; Peng, Bo; Tong, Ziqiu; Wei, Yingkai; Tong, Wing Yin; Thissen, Helmut; Voelcker, Nicolas Hans.

In: Trends in Biotechnology, 23.05.2019.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Advances in Microfluidic Blood–Brain Barrier (BBB) Models

AU - Oddo, Arianna

AU - Peng, Bo

AU - Tong, Ziqiu

AU - Wei, Yingkai

AU - Tong, Wing Yin

AU - Thissen, Helmut

AU - Voelcker, Nicolas Hans

PY - 2019/5/23

Y1 - 2019/5/23

N2 - Therapeutic options for neurological disorders currently remain limited. The intrinsic complexity of the brain architecture prevents potential therapeutics from reaching their cerebral target, thus limiting their efficacy. Recent advances in microfluidic technology and organ-on-chip systems have enabled the development of a new generation of in vitro platforms that can recapitulate complex in vivo microenvironments and physiological responses. In this context, microfluidic-based in vitro models of the blood–brain barrier (BBB) are of particular interest as they provide an innovative approach for conducting research related to the brain, including modeling of neurodegenerative diseases and high-throughput drug screening. Here, we present the most recent advances in BBB-on-chip devices and examine validation steps that will strengthen their future applications.

AB - Therapeutic options for neurological disorders currently remain limited. The intrinsic complexity of the brain architecture prevents potential therapeutics from reaching their cerebral target, thus limiting their efficacy. Recent advances in microfluidic technology and organ-on-chip systems have enabled the development of a new generation of in vitro platforms that can recapitulate complex in vivo microenvironments and physiological responses. In this context, microfluidic-based in vitro models of the blood–brain barrier (BBB) are of particular interest as they provide an innovative approach for conducting research related to the brain, including modeling of neurodegenerative diseases and high-throughput drug screening. Here, we present the most recent advances in BBB-on-chip devices and examine validation steps that will strengthen their future applications.

KW - blood–brain barrier

KW - brain disorders

KW - drug screening

KW - in vitro models

KW - microfluidics

KW - organ-on-chip

UR - http://www.scopus.com/inward/record.url?scp=85065909894&partnerID=8YFLogxK

U2 - 10.1016/j.tibtech.2019.04.006

DO - 10.1016/j.tibtech.2019.04.006

M3 - Review Article

JO - Trends in Biotechnology

JF - Trends in Biotechnology

SN - 0167-7799

ER -